LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 56

Search options

  1. Article ; Online: Analysis of clinical factors impacting recurrence in myxofibrosarcoma.

    Chen, Wenlin / Ye, Ming / Sun, Ye / Wei, Yongzhong / Huang, Yumin

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 3903

    Abstract: Myxofibrosarcoma (MFS) is a malignant fibroblastic/myofibroblastic neoplasm with a prominent myxoid area. It has the clinical features of frequent local recurrence (LR) and occasional distant metastasis. Robust epidemiological data on MFS in China are ... ...

    Abstract Myxofibrosarcoma (MFS) is a malignant fibroblastic/myofibroblastic neoplasm with a prominent myxoid area. It has the clinical features of frequent local recurrence (LR) and occasional distant metastasis. Robust epidemiological data on MFS in China are lacking. The aim of this retrospective analysis was to determine the natural history of MFS, identify prognostic factors for recurrence and describe the real-life outcomes of MFS. We reviewed 52 patients with primary MFS from the First Affiliated Hospital of Nanjing Medical University diagnosed between 2016 and 2020. All tumors were subjected to retrospective univariate analysis for prognostic factors of the disease, including tumor size, grade, location and sex; patient age; planned operation; surgical margin; and laboratory results. The significant factors identified by univariate analysis were subsequently analyzed via multivariate analysis. Overall survival (OS), post-treatment LR and metastatic-free survival were assessed as outcomes. The median age was 61 years (range, 13-93). Fourteen (26.92%) patients exhibited low grade disease, and 38 (73.08%) exhibited high grade disease. Among the 29 males, and 23 females, 15 (28.85%) had tumors in the trunk, 37 (71.15%) had tumors in the extremities, 26 had undergone planned surgery, and 26 had unexpected unplanned operation. The margin was negative in 39 (75%) patients and positive in 13 patients (25%). The serum creatine kinase (CK) concentration was high level in 33 (63.46%) patients and low level in 19 (36.54%) patients. The serum lactate dehydrogenase (LDH) levels were low in 23 (44.23%) patients and high in 29 (55.77%) patients. LR was observed in 25 patients (48.08%), and 4 patients developed metastasis. A worse LR rate was found for patients with a low CK level (84.21%) than for those with a high CK level (27.27%) at 5 years (p < 0.05). The LR rate of patients who underwent planned surgery was lower than that of patients who underwent unplanned surgery (p < 0.05). There were significantly more patients with positive margins than patients with negative margins (92.30%, and 33.33%, respectively; p < 0.05). Moreover, superficial tumors were also associated with greater recurrence rate (2/20 [10%]) than deep tumors, (23/32 [71.86%]) [p < 0.05]. The probability of LR in patients with MFS was significantly greater in association with unplanned operations, positive margins, low serum CK levels or superficial tumor depth. These data could help identify high-risk patients; thus, more careful follow-up should be performed for higher-risk patients. Diagnosis and treatment at qualified regular medical centers can reduce the local recurrence rate of MFS.
    MeSH term(s) Male ; Female ; Adult ; Humans ; Middle Aged ; Retrospective Studies ; Fibrosarcoma/surgery ; Fibrosarcoma/pathology ; Extremities/pathology ; Prognosis ; Histiocytoma, Malignant Fibrous/pathology ; Neoplasm Recurrence, Local/pathology
    Language English
    Publishing date 2024-02-16
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-53606-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: 3D-bioprinted gradient-structured scaffold generates anisotropic cartilage with vascularization by pore-size-dependent activation of HIF1α/FAK signaling axis.

    Sun, Ye / Wu, Qiang / Zhang, Yuxin / Dai, Kerong / Wei, Yongzhong

    Nanomedicine : nanotechnology, biology, and medicine

    2021  Volume 37, Page(s) 102426

    Abstract: Articular cartilage injury is one of the most common diseases in orthopedics, which seriously affects patients' life quality, the development of a biomimetic scaffold that mimics the multi-layered gradient structure of native cartilage is a new cartilage ...

    Abstract Articular cartilage injury is one of the most common diseases in orthopedics, which seriously affects patients' life quality, the development of a biomimetic scaffold that mimics the multi-layered gradient structure of native cartilage is a new cartilage repair strategy. It has been shown that scaffold topography affects cell attachment, proliferation, and differentiation; the underlying molecular mechanism of cell-scaffold interaction is still unclear. In the present study, we construct an anisotropic gradient-structured cartilage scaffold by three-dimensional (3D) bioprinting, in which bone marrow stromal cell (BMSC)-laden anisotropic hydrogels micropatterns were used for heterogeneous chondrogenic differentiation and physically gradient synthetic poly (ε-caprolactone) (PCL) to impart mechanical strength. In vitro and in vivo, we demonstrated that gradient-structured cartilage scaffold displayed better cartilage repair effect. The heterogeneous cartilage tissue maturation and blood vessel ingrowth were mediated by a pore-size-dependent mechanism and HIF1α/FAK axis activation. In summary, our results provided a theoretical basis for employing 3D bioprinting gradient-structured constructs for anisotropic cartilage regeneration and revealed HIF1α/FAK axis as a crucial regulator for cell-material interactions, so as to provide a new perspective for cartilage regeneration and repair.
    MeSH term(s) Animals ; Anisotropy ; Bioprinting ; Cartilage, Articular/growth & development ; Cartilage, Articular/injuries ; Cartilage, Articular/metabolism ; Cartilage, Articular/pathology ; Cell Differentiation/drug effects ; Chondrogenesis/genetics ; Disease Models, Animal ; Focal Adhesion Kinase 1/genetics ; Humans ; Hydrogels/chemistry ; Hydrogels/pharmacology ; Hypoxia-Inducible Factor 1, alpha Subunit/genetics ; Mesenchymal Stem Cells/metabolism ; Polyesters/pharmacology ; Printing, Three-Dimensional ; Rabbits ; Regeneration/drug effects ; Regeneration/genetics ; Signal Transduction/drug effects ; Tissue Engineering ; Tissue Scaffolds/chemistry ; Transcriptome/genetics
    Chemical Substances HIF1A protein, human ; Hydrogels ; Hypoxia-Inducible Factor 1, alpha Subunit ; Polyesters ; polycaprolactone (24980-41-4) ; Focal Adhesion Kinase 1 (EC 2.7.10.2) ; PTK2 protein, human (EC 2.7.10.2)
    Language English
    Publishing date 2021-06-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2183417-9
    ISSN 1549-9642 ; 1549-9634
    ISSN (online) 1549-9642
    ISSN 1549-9634
    DOI 10.1016/j.nano.2021.102426
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: First-Line Anlotinib Treatment for Soft Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-label, Single-arm, Phase 2 Clinical Trial.

    Li, Tao / Dong, Ying / Wei, Yongzhong / Wang, Shoufeng / Liu, Yunxia / Chen, Jia / Xiong, Wenhua / Lin, Nong / Huang, Xin / Liu, Meng / Yan, Xiaobo / Ye, Zhaoming / Li, Binghao

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2024  

    Abstract: Purpose: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) ... ...

    Abstract Purpose: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma (LPS).
    Patients and methods: Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases. Anlotinib was given orally at a dose of 12 mg once daily from day 1 to day 14 every 3 weeks until disease progression or intolerable adverse events (AEs) occurred. The primary endpoint was progression-free survival (PFS) and the secondary endpoints overall survival (OS), the objective response rate and the disease control rate (DCR). The safety profile was also evaluated.
    Results: Forty patients were enrolled from April 2019 to Jun 2022 and are included in the intention-to-treat analysis. The median PFS was 6.83 months [95% confidence interval (CI): 4.17-8.71] and the median OS 27.40 months (95% CI: 16.43-not evaluable); 1 patient reached partial response and 26 attained stable disease, with a DCR of 67.5% (27/40). Median PFS and OS times for LPS patients were 8.71 and 16.23 months, respectively. Ten (25.0%) patients had treatment-related AEs ≥ grade 3, with in particular a higher incidence of hypertension (15.0%) and proteinuria (7.5%).
    Conclusions: The findings suggest a potential benefit in employing front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the LPS subgroup of patients were encouraging.
    Language English
    Publishing date 2024-03-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-3983
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Erratum: 3D-bioprinting ready-to-implant anisotropic menisci recapitulate healthy meniscus phenotype and prevent secondary joint degeneration: Erratum.

    Sun, Ye / Zhang, Yuxin / Wu, Qiang / Gao, Feng / Wei, Yongzhong / Ma, Yimin / Jiang, Wenbo / Dai, Kerong

    Theranostics

    2022  Volume 12, Issue 10, Page(s) 4601–4602

    Abstract: This corrects the article DOI: 10.7150/thno.54864.]. ...

    Abstract [This corrects the article DOI: 10.7150/thno.54864.].
    Language English
    Publishing date 2022-05-28
    Publishing country Australia
    Document type Published Erratum
    ZDB-ID 2592097-2
    ISSN 1838-7640 ; 1838-7640
    ISSN (online) 1838-7640
    ISSN 1838-7640
    DOI 10.7150/thno.73783
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Systemic leptin administration alters callus VEGF levels and enhances bone fracture healing in wildtype and ob/ob mice.

    Wu, Zhisheng / Shao, Peng / Dass, Crispin R / Wei, Yongzhong

    Injury

    2018  Volume 49, Issue 10, Page(s) 1739–1745

    Abstract: Introduction: Leptin's role in bone formation has been reported, however, its mechanism of affecting bone metabolism is remaining unclear. In this study, we aimed to test whether leptin has a positive effect on fracture healing through the possible ... ...

    Abstract Introduction: Leptin's role in bone formation has been reported, however, its mechanism of affecting bone metabolism is remaining unclear. In this study, we aimed to test whether leptin has a positive effect on fracture healing through the possible mechanism of increasing vascular endothelial growth factor (VEGF) expression in callus tissue.
    Methods: Standardized femur fractures were created in leptin-deficient ob/ob and wildtype C57BL/6J mice, and recombinant mouse leptin or its vehicle (physiological saline) was administered intraperitoneally during the study. Body weight, radiological, histologic and immunoblotting analyses were performed at different stages of fracture healing.
    Key findings: The results showed that leptin treatment led to lower rate of body weight change in both mice genotypes. Radiological and histological analyses showed that the experimental groups had better fracture healing at 14, 21 and 28 days compared to the control groups. Leptin-treated groups had significantly higher VEGF expression in callus compared with the control groups at 2 and 3 weeks post-fracture except normal mice at 2 weeks, and leptin-deficient mice had higher VEGF levels in calluses than normal mice at the same timepoint.
    Conclusion: Low-dose systemically-administered leptin has a positive effect on promoting fracture healing during the latter stages in a clinically-relevant mouse bone fracture model, and increase callus VEGF levels.
    MeSH term(s) Animals ; Bony Callus/metabolism ; Disease Models, Animal ; Femoral Fractures/drug therapy ; Femoral Fractures/metabolism ; Femoral Fractures/physiopathology ; Fracture Healing/physiology ; Injections, Intraperitoneal ; Leptin/administration & dosage ; Leptin/deficiency ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Obese ; RNA, Messenger/metabolism ; Tomography, X-Ray Computed ; Vascular Endothelial Growth Factor A/metabolism
    Chemical Substances Leptin ; RNA, Messenger ; Vascular Endothelial Growth Factor A
    Language English
    Publishing date 2018-07-02
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 218778-4
    ISSN 1879-0267 ; 0020-1383
    ISSN (online) 1879-0267
    ISSN 0020-1383
    DOI 10.1016/j.injury.2018.06.040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Exosomal transfer of miR-769-5p promotes osteosarcoma proliferation and metastasis by targeting DUSP16.

    Liu, Wanshun / Wang, Binyu / Duan, Ao / Shen, Kai / Zhang, Qi / Tang, Xiaolu / Wei, Yongzhong / Tang, Jian / Zhang, Sheng

    Cancer cell international

    2021  Volume 21, Issue 1, Page(s) 541

    Abstract: Background: Osteosarcoma (OS) is a malignant tumor originating from mesenchymal stem cells, and has an extremely high fatality rate and ability to metastasize. Although mounting evidence suggests that miR-769-5p is strongly associated with the malignant ...

    Abstract Background: Osteosarcoma (OS) is a malignant tumor originating from mesenchymal stem cells, and has an extremely high fatality rate and ability to metastasize. Although mounting evidence suggests that miR-769-5p is strongly associated with the malignant progression and poor prognosis of various tumors, the exact role of miR-769-5p in OS is still unclear. Therefore, this study aimed to explore the relationship between miR-769-5p and the malignant progression of OS, and its underlying mechanism of action.
    Methods: miR-769-5p expression was analyzed in GSE28423 from the GEO database and measured in OS clinical specimens and cell lines. The effects of miR-769-5p on OS proliferation, migration and invasion were measured both in vivo and in vitro. In addition, bioinformatics analyses and luciferase reporter assays were used to explore the target genes of miR-769-5p. Rescue experiments were also conducted. Moreover, a co-culture model was used to test the cell interaction between bone mesenchymal stem cells (BMSC) and OS cells.
    Results: We found that miR-769-5p is highly expressed in OS clinical specimens and cell lines. In vivo and in vitro experiments also showed that miR-769-5p significantly promoted the proliferation, migration and invasion of OS cells. Dual-specific phosphatase 16 (DUSP16) was negatively associated with miR-769-5p expression in OS cells and tissue samples and was validated as the downstream target by luciferase reporter assay and western blotting. Rescue experiments showed that DUSP16 reverses the effect of miR-769-5p on OS cells by negatively regulating the JNK/p38 MAPK signaling pathway. Additionally, the results of the co-culture of BMSCs and OS cells confirmed that miR-769-5p was transferred from BMSCs to OS cells through exosomes.
    Conclusions: In summary, this study demonstrates for the first time that BMSC-derived exosomal miR-769-5p promotes OS proliferation and metastasis by targeting DUSP16 and activating the JNK/p38 MAPK signaling pathway, which could provide rationale for a new therapeutic strategy for OS.
    Language English
    Publishing date 2021-10-18
    Publishing country England
    Document type Journal Article
    ISSN 1475-2867
    ISSN 1475-2867
    DOI 10.1186/s12935-021-02257-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: 3D-bioprinting ready-to-implant anisotropic menisci recapitulate healthy meniscus phenotype and prevent secondary joint degeneration.

    Sun, Ye / Zhang, Yuxin / Wu, Qiang / Gao, Feng / Wei, Yongzhong / Ma, Yimin / Jiang, Wenbo / Dai, Kerong

    Theranostics

    2021  Volume 11, Issue 11, Page(s) 5160–5173

    Abstract: Objectives: ...

    Abstract Objectives:
    MeSH term(s) Animals ; Anisotropy ; Bioprinting/methods ; Knee Joint/pathology ; Meniscus/pathology ; Phenotype ; Rabbits ; Tissue Engineering/methods
    Language English
    Publishing date 2021-03-05
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2592097-2
    ISSN 1838-7640 ; 1838-7640
    ISSN (online) 1838-7640
    ISSN 1838-7640
    DOI 10.7150/thno.54864
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Epidemiology of extrapulmonary tuberculosis in central Guangxi from 2016 to 2021.

    Li, Lanxiang / Lv, Yu / Su, Lingsong / Liu, Qianyu / Lan, Ke / Wei, Di / Wu, Qingguo / Hu, Yanling / Lv, Jiannan / Pang, Xianwu / Xie, Bo / Liu, Zengjing / Wei, Xihua / Liu, Aimei / Leng, Jing / Wei, Yongzhong

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2022  

    Abstract: The burden of extrapulmonary tuberculosis (EPTB) has gradually increased in recent years, but not enough epidemiological data is available from central Guangxi. To better understand the epidemiology of EPTB in central Guangxi and identify risk factors ... ...

    Abstract The burden of extrapulmonary tuberculosis (EPTB) has gradually increased in recent years, but not enough epidemiological data is available from central Guangxi. To better understand the epidemiology of EPTB in central Guangxi and identify risk factors associated with them, we retrospectively investigated the epidemiology of tuberculosis (TB), especially EPTB, among patients admitted to the Chest Hospital of Guangxi Zhuang Autonomous Region between 2016 and 2021. We excluded those infected with both pulmonary tuberculosis (PTB) and EPTB, reported the proportion and incidence of PTB or EPTB, and compared the demographic characteristics and risk factors of EPTB and PTB cases using univariate and multivariate logistic regression models. Among 30,893 TB patients, 67.25% (20,774) had PTB and 32.75% (10,119) had EPTB. Among EPTB, pleural, skeletal, lymphatic, pericardial, meningeal, genitourinary, intestinal, and peritoneal TB accounted for 49.44%, 27.20%, 8.55%, 4.39%, 3.36%, 1.48%, 0.87%, and 0.79%, respectively. Patients who were younger (age < 25), from rural areas, Zhuang and other ethnic groups, and diagnosed with anemia and HIV infection were more likely to develop EPTB. However, patients with diabetes and COPD were less likely to have EPTB. From 2016 to 2021, the proportion of PTB cases decreased from 69.73 to 64.07%. The percentage of EPTB cases increased from 30.27 to 35.93%, with the largest increase in skeletal TB from 21.48 to 34.13%. The epidemiology and risk factors of EPTB in central Guangxi are different from those of PTB. The incidence of EPTB is increasing and further studies are needed to determine the reasons for it.
    Language English
    Publishing date 2022-11-29
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-022-04524-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.

    Li, Juming / Liu, Lingxiang / Zhang, Qi / Huang, Yumin / Zhang, Yihong / Gan, Xiaoyan / Liu, Siqin / Yue, Zhen / Wei, Yongzhong

    Medicine

    2020  Volume 99, Issue 26, Page(s) e20725

    Abstract: Rationale: Malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma. Owing to the lack of specific histological criteria, immunohistochemical, and molecular diagnostic markers, several differential diagnoses must be considered. Advances in ... ...

    Abstract Rationale: Malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma. Owing to the lack of specific histological criteria, immunohistochemical, and molecular diagnostic markers, several differential diagnoses must be considered. Advances in molecular testing can provide significant insights for management of rare tumor.
    Patient concerns: The patient was a 50-year-old man with a history of lumpectomy on the right back 30 years ago. He felt a stabbing pain at the right iliac fossa and went to the local hospital.
    Diagnosis: By immunohistochemistry, the tumor cells stained positively for S-100 (focal +), CD34 (strong +++) and Ki-67 (20%), and negatively for smooth muscle actin, pan-cytokeratin, neurofilament, pan-cytokeratin-L, GFAP, CD31, STAT6, ERG, myogenin, and MyoD1. Combined with the histopathology and immunohistochemistry results, our initial diagnosis was solitary fibrous tumor (SFT) or MPNST. The tissue biopsy was sent for next-generation sequencing. neurofibromatosis type 1 Q1395Hfs*22 somatic mutation, neurofibromatosis type 1 D483Tfs*15 germline mutation, and amplifications of BTK, MDM2, ATF1, BMPR1A, EBHA2, GNA13, PTPN11, RAD52, RPTOR, and SOX9, as well as TJP1-ROS1 fusion, CDKN2A-IL1RAPL2 fusion and CDKN2A/UBAP1 rearrangement were identified. Given that NAB2-STAT6 fusion, a specific biomarker of SFT, was not identified in our patient's tumor, the SFT was excluded by through genetic testing results. Therefore, our finally diagnosis was a MPNST by 2 or more pathologists.
    Interventions and outcomes: Subsequently, the patient received crizotinib therapy for 2 months and showed stable disease. However, after crizotinib continued treatment for 4 months, the patient's disease progressed. Soon after, the patient stopped crizotinib treatment and died in home.
    Lessons: To our knowledge, this is the first report of the TJP1-ROS1 fusion, which expands the list of gene fusions and highlights new targets for targeted therapy. Also, our case underlines the value of multi-gene panel next-generation sequencing for diagnosis of MPNST.
    MeSH term(s) Antineoplastic Agents/administration & dosage ; Crizotinib/administration & dosage ; Diagnosis, Differential ; Disease Progression ; Drug Monitoring ; Gene Fusion/genetics ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Neoplasms, Fibrous Tissue/diagnosis ; Neurofibrosarcoma/drug therapy ; Neurofibrosarcoma/genetics ; Neurofibrosarcoma/pathology ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Treatment Outcome ; Zonula Occludens-1 Protein/genetics
    Chemical Substances Antineoplastic Agents ; Proto-Oncogene Proteins ; TJP1 protein, human ; Zonula Occludens-1 Protein ; Crizotinib (53AH36668S) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; ROS1 protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2020-07-06
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 80184-7
    ISSN 1536-5964 ; 0025-7974
    ISSN (online) 1536-5964
    ISSN 0025-7974
    DOI 10.1097/MD.0000000000020725
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Fibrosarcoma development 15 years after curettage and bone grafting of giant cell tumor of bone.

    Li, JuMing / Zhu, Yan / Wei, YongZhong

    Orthopedics

    2014  Volume 37, Issue 5, Page(s) e512–6

    Abstract: Malignant transformation of conventional giant cell tumor of bone is rare and usually occurs with irradiation. This article describes a case of malignant transformation of a giant cell tumor 15 years after initial curettage and bone graft. A 35-year-old ... ...

    Abstract Malignant transformation of conventional giant cell tumor of bone is rare and usually occurs with irradiation. This article describes a case of malignant transformation of a giant cell tumor 15 years after initial curettage and bone graft. A 35-year-old man was admitted to the hospital with a recurrent giant cell tumor of the distal femur. On presentation, the patient reported the insidious onset of a dull aching pain in the distal part of the left thigh 4 months prior to admission. Radiographs revealed a destructive lesion in the left distal femur. Needle biopsy revealed recurrence of giant cell tumor with suspected malignant transformation. The patient underwent en bloc resection of the distal femur with adequately wide margins and reconstruction of the knee joint with a prosthesis. Pathological findings showed malignant transformation of a giant cell tumor to high-grade spindle cell sarcoma. Immunohistochemistry showed diffuse and strong p53 expression. A diagnosis of secondary fibrosarcoma was made after discussion. Unfortunately, the tumor proved to be highly resistant to the chemotherapy, and the patient died of multiple lung metastases 14 months after the diagnosis of malignant transformation. What has to be stressed in this case is that any late recurrence must be approached considering the possibility of a secondary induced primary tumor. Because of the rarity of this disease, the effective therapeutic strategy for fibrosarcoma secondary to giant cell tumor is lacking. In addition, identification of the p53 mutation may help in diagnosing cases of potential malignant transformation of giant cell tumor.
    MeSH term(s) Adult ; Bone Transplantation ; Cell Transformation, Neoplastic/pathology ; Curettage ; Fatal Outcome ; Femoral Neoplasms/pathology ; Femoral Neoplasms/surgery ; Fibrosarcoma/pathology ; Fibrosarcoma/surgery ; Giant Cell Tumor of Bone/pathology ; Giant Cell Tumor of Bone/surgery ; Humans ; Lung Neoplasms/secondary ; Male ; Neoplasm Recurrence, Local
    Language English
    Publishing date 2014-05
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 424447-3
    ISSN 1938-2367 ; 0147-7447
    ISSN (online) 1938-2367
    ISSN 0147-7447
    DOI 10.3928/01477447-20140430-66
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top